ATNM — Actinium Pharmaceuticals Share Price
Last Trade - 00:00- $137.16m
- $55.36m
- $0.89m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 1.14 | 19.05 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
Directors
- Sandesh Seth CHM (55)
- Steve O'Loughlin (35)
- Dale Ludwig (58)
- Mark Berger (65)
- C. David Nicholson (64)
- Jeffrey Chell (65)
- Ajit Shetty (74)
- Richard Steinhart (64)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- March 20th, 2013
- Public Since
- March 26th, 2014
- No. of Shareholders
- 99
- No. of Employees
- 32
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 21,331,314
- Address
- 275 Madison Ave Fl 7, NEW YORK, 10016-1101
- Web
- https://www.actiniumpharma.com/
- Phone
- +1 6466773875
- Auditors
- Marcum LLP
Latest News for ATNM
Upcoming events for ATNM
Similar to ATNM
AGEX THERAPEUTICS ORD
NYSE MKT
AIM IMMUNOTECH ORD
NYSE MKT
AMPIO PHARMACEUTICALS ORD
NYSE MKT
ANNOVIS BIO ORD
NYSE MKT
BIOMX ORD
NYSE MKT
FAQ
As of Today at 19:55 UTC, shares in Actinium Pharmaceuticals are trading at $6.43. This share price information is delayed by 15 minutes.
Shares in Actinium Pharmaceuticals last closed at $6.43 and the price had moved by -40.52% over the past 365 days. In terms of relative price strength the Actinium Pharmaceuticals share price has underperformed the S&P500 Index by -54.87% over the past year.
The overall consensus recommendation for Actinium Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Actinium Pharmaceuticals does not currently pay a dividend.
Actinium Pharmaceuticals does not currently pay a dividend.
Actinium Pharmaceuticals does not currently pay a dividend.
To buy shares in Actinium Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.43, shares in Actinium Pharmaceuticals had a market capitalisation of $137.16m.
Here are the trading details for Actinium Pharmaceuticals:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: ATNM
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Actinium Pharmaceuticals does not currently have a style classification.
The analyst consensus target price for shares in Actinium Pharmaceuticals is $33.75. That is 424.88% above the last closing price of $6.43.
Analysts covering Actinium Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.12 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actinium Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -36.26%.
As of the last closing price of $6.43, shares in Actinium Pharmaceuticals were trading -24.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Actinium Pharmaceuticals.
Actinium Pharmaceuticals' management team is headed by:
- Sandesh Seth - CHM
- Steve O'Loughlin -
- Dale Ludwig -
- Mark Berger -
- C. David Nicholson -
- Jeffrey Chell -
- Ajit Shetty -
- Richard Steinhart -
We do not have data on Actinium Pharmaceuticals' shareholders